BDTX - Latest News

Black Diamond Therapeutics, Inc. (BDTX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $163.9M. Beta to the broader market is 3.35.

The article list below shows the most recent BDTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent BDTX Headlines

BDTX Shares Gain 11% in a Week: Here's What You Should Know

zacks.com - May 11, 2026

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

globenewswire.com - May 7, 2026

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 AS

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

zacks.com - Apr 28, 2026

Investors need to pay close attention to BDTX stock based on the movements in the options market lately.

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

zacks.com - Apr 23, 2026

Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asse

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

zacks.com - Apr 23, 2026

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung c

How News Affects BDTX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BDTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked BDTX news questions

What is the latest BDTX news headline?

The most recent BDTX headline (May 11, 2026) is "BDTX Shares Gain 11% in a Week: Here's What You Should Know". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the BDTX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What BDTX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual BDTX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.